A Clinical Study to Evaluate the Effect of Mobile Applications "My A:Care" and "Smart Coach" on the Lipid-lowering Treatment Adherence of Subjects With Dyslipidemia in Thailand

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-04-26

Study Completion Date

2022-11-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A prospective, randomized, open-label, clinical study to evaluate the effect of mobile applications "My A:Care" and "Smart Coach" on the lipid-lowering treatment adherence of subjects with dyslipidemia in Thailand

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

AdLip: Human Coach-supported Digital/AI Personal Health Assistant to Improve Adherence to Lipid-Lowering Medication

NCT06614049

Hyperlipidemia Medication Nonadherence

RECRUITING NA

Medication Adherence Program

NCT05183763

Hypertension Medication Adherence Behavior and Behavior Mechanisms

RECRUITING NA

Pilot Program to Improve Statin Adherence and Lower Cholesterol in Older Adults

NCT01227330

Hypercholesterolemia Medication Adherence

COMPLETED PHASE1/PHASE2

Social Forces to Improve Statin Adherence (Study A)

NCT02018809

Medication Adherence High Blood Pressure Diabetes

COMPLETED NA

Translating ATP III Cholesterol Management Guidelines Into Primary Care Practice

NCT01242319

Hypercholesterolemia Coronary Disease Primary Health Care +1 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective, randomized, open-label, clinical study in subjects with dyslipidemia and suboptimal adherence to their current lipid-lowering therapy in Thailand. Suboptimal adherence is defined as having \<22 points score on the Part 1 of MARS-5VA questionnaire. This questionnaire comprises 2 parts, Medication Adherence Report Scale (MARS-5) as Part 1 and two Visual Analogue Scales (VAS) as Part 2. The complete MARS-5VA questionnaire (Part 1 and 2) will be used to evaluate subject adherence to lipid-lowering therapy in the study. The Part 1 of MARS-5VA will also be used to confirm subject's eligibility at screening. Subjects who are continuing the stable lipid-lowering therapy for at least 1 month are being considered for this study. Subjects will be randomized to different types of behavior interventions using mobile applications that will be used in addition to their current standard of care (SOC) lipid-lowering therapy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dyslipidemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Standard of Care (SOC) group

This group will continue their current lipid-lowering therapy and will not need to download any mobile application.

No interventions assigned to this group

SOC + My A:Care group:

This group will continue their current lipid-lowering therapy along with access to the mobile application My A:Care that supports medication adherence through motivational messages and challenges, health insights, and medication reminders.

My A:care

Intervention Type BEHAVIORAL

Mobile application with Motivational messages

SOC + Smart Coach group:

This group will continue their current lipid-lowering therapy along with access to the mobile application Smart Coach that supports medication adherence through personalized motivational messages and challenges, health insights, and medication reminders. Personalization of the messages and challenges will be based on a behavioral profiling Social, Psychological, Usage, Rational (SPUR™) questionnaire that is completed at randomization to the Smart Coach application.

Study site will guide the subjects on how to use these mobile applications. Eligibility assessment will be based on information collected at screening/baseline visit (Visit 1) and assessment of Part 1 of MARS 5VA questionnaire. Adherence at baseline (Visit 1) and after 12 weeks of observation (Visit 2), will be evaluated by the complete MARS 5VA (Part 1 and 2) questionnaire. Each subject will be followed up for approximately 12 weeks from randomization at Visit 1.

Smart Coach

Intervention Type BEHAVIORAL

Mobile application with Motivational messages

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

My A:care

Mobile application with Motivational messages

Intervention Type BEHAVIORAL

Smart Coach

Mobile application with Motivational messages

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male and female subjects aged 18-75 years (inclusive)
2. Subjects who have provided written informed consent
3. Subjects who were diagnosed with dyslipidemia and initiated lipid-lowering therapy based on local treatment guidelines, between 9 months and 1 month prior to the screening visit
4. Subjects who were on a stable lipid-lowering therapy within 1 month prior to the screening visit
5. Subjects who are not compliant with the prescribed lipid-lowering therapy, assessed as having \<22 points score on the Part 1 of MARS-5VA questionnaire at the screening visit
6. Subjects for whom lipid profile laboratory data is available from routine care within 14 days prior to the screening visit
7. Subject must have their own Android operating system smart phone and a data package suitable for the installation and running of the mobile application and sending and receiving data
8. Willing and able to operate the mobile devices, including use of all study-related smartphone applications; able to proof regular use of mobile applications in their daily life.
9. Able to read and understand Thai
10. Willing and able to comply with the study requirements.

Exclusion Criteria

1. Subjects who are diagnosed with myocardial infarction or stroke or unstable angina within 2 months prior to screening, subjects who are hospitalized for their cardio-vascular condition and requiring changes in administration of their lipid-lowering medication
2. Subjects who experienced undesirable effects of their lipid-lowering medication and who might, in the opinion of the investigator, require its modification or discontinuation during the 12 weeks of observation period of the study
3. Subjects receiving injectable lipid-lowering therapy
4. Subjects who are currently using other medication-use-related mobile applications.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No